截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新世紀醫療控股有限公司 呈交日期: 2025年10月9日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 股份發行人及根據《上市規則》第十九B章上市的香港 ...

New Century Healthcare Holding Co. Limited 新世紀醫療控股有限公司 （於開曼群島註冊成立的有限公司） 股份代號：1518 2025 (Incorporated in the Cayman Islands with limited liability) Stock Code: 1518 New Century Healthcare Holding Co. Limited 新世紀醫療控股有限公司 INTERIM REPORT 2025 中期報 告 New Century Healthcare Holding Co. Li mited 新 世 紀 醫 療 控 股 有 限 公 司 中 期 報 告 IN T E RIM R E P O R T 股 代 號 Stock Code: 1518 2025 目錄 | 公司資料 | 2 | | --- | --- | | 管理層討論與分析 | 4 | | 其他資料 | 13 | | 中期財務資料的審閱報告 | 20 | | 中期簡明綜合財務狀況表 | 21 | | 中期簡明綜合全面收益表 | 23 | | 中期簡明綜合權益變動表 | 24 ...

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： USD 100,000 FF301 第 1 頁 共 10 頁 v 1.1.1 公司名稱: 新世紀醫療控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年9 ...

Group 1 - The company, New Century Healthcare (01518), reported a revenue of 305 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 26.79% [1] - The company recorded a loss attributable to owners of 65.234 million RMB, marking a shift from profit to loss compared to the previous year [1] - The basic loss per share was reported at 0.14 RMB [1]

Core Viewpoint - New Century Healthcare (01518.HK) reported a significant decline in revenue and incurred losses for the six months ending June 30, 2025, primarily due to reduced demand for pediatric and obstetric services [1] Financial Performance - Revenue for the period was RMB 305 million, representing a year-on-year decrease of 26.8% [1] - The loss attributable to the company's owners was RMB 65.234 million, compared to a profit of RMB 25.193 million in the same period last year [1] - Basic loss per share was RMB 0.14 [1] Loss Drivers - The company recorded a pre-tax loss of RMB 41.1 million, contrasting with a pre-tax profit of RMB 72.2 million in the previous year [1] - The decline in revenue was mainly attributed to a decrease in demand for pediatric and obstetric services, resulting in a revenue drop of RMB 111.5 million [1] - Additionally, the company faced impairment losses of RMB 12.5 million related to goodwill and RMB 21.2 million related to property, plant, and equipment [1]

Core Viewpoint - New Century Healthcare (01518) reported a significant loss for the six months ending June 30, 2025, with a shift from profit to loss compared to the previous year [1] Financial Performance - The company achieved revenue of 305 million RMB, representing a year-on-year decrease of 26.79% [1] - The loss attributable to shareholders was 65.234 million RMB, marking a transition from profit to loss compared to the same period last year [1] - Basic loss per share was reported at 0.14 RMB [1]

Interim Results Announcement [2025 Interim Results Summary](index=1&type=section&id=2025%20Interim%20Results%20Summary) The Group reported RMB304.5 million in revenue and a RMB41.1 million loss before tax for H1 2025, driven by reduced service demand and asset impairment Key Operating Data (For the six months ended June 30) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Outpatient medical services revenue | 182,520 | 244,616 | (25.4)% | | Outpatient visits | 103,344 | 141,128 | (26.8)% | | Inpatient medical services revenue | 102,786 | 145,285 | (29.3)% | | Inpatient visits | 3,411 | 4,429 | (23.0)% | - For the six months ended June 30, 2025, revenue was **RMB304.5 million**, a decrease compared to the prior period[4](index=4&type=chunk) - For the six months ended June 30, 2025, the Group recorded a **loss before income tax of RMB41.1 million**, compared to a profit of RMB72.2 million in the prior period[4](index=4&type=chunk) - The loss was primarily due to a **RMB111.5 million decrease in revenue** from reduced demand for pediatric and obstetrics & gynecology services, along with a **goodwill impairment loss of RMB12.5 million** and an **impairment loss on property, plant and equipment of RMB21.2 million**[4](index=4&type=chunk) [Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited interim condensed consolidated financial statements for H1 2025, reflecting a shift from profit to loss and reduced asset and equity values [Interim Condensed Consolidated Statement of Comprehensive Income](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For H1 2025, the Group reported RMB304,528 thousand in revenue, an operating loss of RMB40,095 thousand, and a loss attributable to owners of RMB65,234 thousand Interim Condensed Consolidated Statement of Comprehensive Income (Summary) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Revenue | 304,528 | 415,956 | | Cost of revenue | (214,882) | (247,237) | | Impairment loss on non-current assets | (33,737) | — | | Operating (loss)/profit | (40,095) | 72,363 | | (Loss)/profit before income tax | (41,088) | 72,169 | | Income tax expense | (17,719) | (23,862) | | (Loss)/profit for the interim period | (58,807) | 48,307 | | (Loss)/profit attributable to owners of the Company | (65,234) | 25,193 | | Basic and diluted (loss)/earnings per share (RMB) | (0.14) | 0.05 | [Interim Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets decreased to RMB836,782 thousand, with equity attributable to owners at RMB478,856 thousand and total liabilities at RMB396,449 thousand Interim Condensed Consolidated Statement of Financial Position (Summary) | Indicator | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Total non-current assets | 424,203 | 478,712 | | Total current assets | 412,579 | 460,422 | | Total assets | 836,782 | 939,134 | | Equity attributable to owners of the Company | 478,856 | 553,826 | | Total equity | 440,333 | 508,876 | | Total non-current liabilities | 122,642 | 137,979 | | Total current liabilities | 273,807 | 292,279 | | Total liabilities | 396,449 | 430,258 | | Total equity and liabilities | 836,782 | 939,134 | [Notes to Interim Condensed Consolidated Financial Information](index=6&type=section&id=Notes%20to%20Interim%20Condensed%20Consolidated%20Financial%20Information) This section provides notes to the interim condensed consolidated financial information, detailing business nature, reporting basis, segment data, tax, EPS, receivables, payables, and dividends [General Information](index=6&type=section&id=General%20Information) The Group primarily offers pediatric and obstetrics & gynecology specialist services in China, including online medical services, and was listed on the HKEX in 2017 - The Group primarily provides **pediatric and obstetrics & gynecology specialist services** in China, along with online medical services[11](index=11&type=chunk) - The Company was incorporated in the Cayman Islands on July 31, 2015, and listed on the Main Board of the Hong Kong Stock Exchange on January 18, 2017[11](index=11&type=chunk)[12](index=12&type=chunk) [Basis of Preparation of Interim Report](index=6&type=section&id=Basis%20of%20Preparation%20of%20Interim%20Report) The interim condensed consolidated financial information is prepared under HKAS 34, consistent with prior year policies, and new standards are not expected to have a significant impact - The interim condensed consolidated financial information is prepared in accordance with **Hong Kong Accounting Standard 34 "Interim Financial Reporting"**[13](index=13&type=chunk) - The accounting policies adopted are consistent with the previous financial year, except for the adoption of new and revised standards, which are not expected to have a significant impact on the Group[13](index=13&type=chunk)[14](index=14&type=chunk)[15](index=15&type=chunk) [Segment Information](index=7&type=section&id=Segment%20Information) The Group's segments include pediatric, obstetrics & gynecology, and other services, with both pediatric and obstetrics & gynecology revenues decreasing in H1 2025 - The Group primarily operates three segments: **pediatric services, obstetrics & gynecology services, and other services** (including online medical services, restaurants, gift shops, etc)[16](index=16&type=chunk) Segment Revenue and Results (For the six months ended June 30) | Segment | 2025 Revenue (RMB thousands) | 2024 Revenue (RMB thousands) | 2025 Segment Results (RMB thousands) | 2024 Segment Results (RMB thousands) | | :--- | :--- | :--- | :--- | :--- | | Pediatrics | 255,693 | 360,956 | (507) | 95,127 | | Obstetrics & Gynecology | 45,312 | 51,093 | (28,636) | (15,698) | | Others | 3,523 | 3,907 | 2,883 | 546 | | Total (from external customers) | 304,528 | 415,956 | - | - | - The vast majority of revenue from external customers is recognized at a point in time, and all revenue and non-current assets primarily originate from China[19](index=19&type=chunk) [Income Tax Expense](index=8&type=section&id=Income%20Tax%20Expense) Income tax expense for H1 2025 was RMB17,719 thousand, decreasing due to the Group's loss and deferred tax asset reversal, with varying tax rates for Chinese and Hong Kong entities Income Tax Expense (For the six months ended June 30) | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Current income tax — China corporate income tax | 9,200 | 22,786 | | Deferred income tax | 8,519 | 1,076 | | Total | 17,719 | 23,862 | - Mainland China subsidiaries are subject to a **corporate income tax rate of 25%**, with high-tech enterprises enjoying a **preferential rate of 15%**[22](index=22&type=chunk) - Hong Kong profits tax rate is 16.5%, but no tax was payable during the reporting period[23](index=23&type=chunk) [Earnings Per Share](index=9&type=section&id=Earnings%20Per%20Share) For H1 2025, the loss attributable to owners resulted in a basic and diluted loss per share of **RMB0.14**, with no potential dilutive shares Earnings Per Share (For the six months ended June 30) | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | (Loss)/profit attributable to owners of the Company (RMB thousands) | (65,234) | 25,193 | | Weighted average number of ordinary shares outstanding (thousands of shares) | 483,184 | 483,184 | | Basic (loss)/earnings per share (RMB) | (0.14) | 0.05 | - For the six months ended June 30, 2025 and 2024, diluted (loss)/earnings per share were equal to basic (loss)/earnings per share, as there were no potential dilutive shares[26](index=26&type=chunk) [Trade Receivables](index=10&type=section&id=Trade%20Receivables) Net trade receivables decreased by **38.3%** to **RMB28,523 thousand** as of June 30, 2025, primarily from commercial and government insurance Trade Receivables (As of) | Item | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Trade receivables from contracts with customers | 30,219 | 47,683 | | Less: Impairment allowance for trade receivables | (1,696) | (1,533) | | Trade receivables — net | 28,523 | 46,150 | - Trade receivables primarily consist of amounts due from **commercial insurance companies and government insurance schemes**[27](index=27&type=chunk) [Trade Payables](index=11&type=section&id=Trade%20Payables) Total trade payables decreased by **24.1%** to **RMB22,653 thousand** as of June 30, 2025 Trade Payables (As of) | Ageing | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Within 3 months | 16,938 | 22,568 | | 4 to 6 months | 3,036 | 5,602 | | 7 months to 1 year | 1,281 | 458 | | Over 1 year | 1,398 | 1,288 | | Total | 22,653 | 29,916 | [Dividends](index=11&type=section&id=Dividends) For H1 2025, the Company paid a final dividend of **RMB7,996 thousand**, a decrease from the prior period, with no dividends to non-controlling shareholders Dividends Paid (For the six months ended June 30) | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Dividends paid per fully paid ordinary share during the interim period | 7,996 | 14,852 | - For the six months ended June 30, 2025, the Company paid a final dividend of **RMB7,996 thousand** (approximately HK$8,705,000)[29](index=29&type=chunk)[30](index=30&type=chunk) - For the six months ended June 30, 2025, no dividends were declared or paid to non-controlling shareholders of Beijing New Century Children's Hospital Co Ltd, a subsidiary[30](index=30&type=chunk) [Business Overview](index=12&type=section&id=Business%20Overview) The Group's H1 2025 revenue decreased by **26.8%** to **RMB304.5 million**, primarily due to reduced demand for pediatric and obstetrics & gynecology services, prompting new loyalty programs - The Group's business revenue was **RMB304.5 million**, a **26.8% year-over-year decrease**[31](index=31&type=chunk) - Pediatric services revenue was **RMB255.7 million**, a **29.2% year-over-year decrease**; obstetrics & gynecology business revenue was **RMB45.3 million**, an **11.4% year-over-year decrease**[31](index=31&type=chunk) - The significant revenue decrease was primarily due to reduced demand for pediatric and obstetrics & gynecology medical services, influenced by a decline in overall birth rates and lower incidence of internal medicine infectious diseases[32](index=32&type=chunk) - To address the decline in demand, multiple hospital campuses of the Group launched **tiered membership cards and long-term loyalty programs**[32](index=32&type=chunk) - The **loss attributable to owners of the Company was RMB65.2 million**, mainly due to declining business demand and new impairment losses on goodwill, property, plant and equipment[33](index=33&type=chunk) [Industry Outlook & Group Strategy](index=13&type=section&id=Industry%20Outlook%20%26%20Group%20Strategy) National policies and DRG/DIP reforms are shaping the healthcare industry, prompting the Group to focus on brand promotion, tiered membership, pediatric sub-specialties, and staff optimization - National policies, such as the **"Outline for Women's Development in China (2021-2030)"** and the **"Outline for Children's Development in China (2021-2030)"**, promote the development of women's and children's health, leading to significant growth in demand for comprehensive healthcare services[34](index=34&type=chunk) - **DRG/DIP payment reform** imposes higher requirements on the medical technology level of private high-end medical institutions, further highlighting their advantages and attracting individuals seeking quality services, long treatment courses, complex conditions, and mid-to-high-end commercial medical insurance[35](index=35&type=chunk) - The Group's strategy includes: **brand promotion among mid-to-high-end commercial insurance institutions**; promoting a **tiered membership card strategy** to lower renewal thresholds; focusing on **pediatric sub-specialty development** and restructuring child healthcare service product lines; and **optimizing staff structure** to enhance efficiency[37](index=37&type=chunk) [Financial Review](index=14&type=section&id=Financial%20Review) This section reviews the Group's H1 2025 financial performance, highlighting significant declines in revenue, gross profit, and gross margin, a shift to operating loss, and impacts on balance sheet items and liquidity [Segment Revenue](index=14&type=section&id=Segment%20Revenue) Medical services generated **RMB301,005 thousand** in H1 2025, representing **98.8%** of total revenue, with pediatric services contributing **84.0%** and obstetrics & gynecology **14.8%** Revenue Breakdown (For the six months ended June 30) | Item | 2025 (RMB thousands) | Proportion (%) | 2024 (RMB thousands) | Proportion (%) | | :--- | :--- | :--- | :--- | :--- | | Medical services | 301,005 | 98.8% | 412,049 | 99.1% | | Others | 3,523 | 1.2% | 3,907 | 0.9% | | Total | 304,528 | 100.0% | 415,956 | 100.0% | Composition of Pediatric and Obstetrics & Gynecology Services Revenue (For the six months ended June 30) | Service Type | 2025 (RMB thousands) | Proportion (%) | 2024 (RMB thousands) | Proportion (%) | | :--- | :--- | :--- | :--- | :--- | | Pediatric services | 255,693 | 84.0% | 360,956 | 86.8% | | Obstetrics & Gynecology services | 45,312 | 14.8% | 51,093 | 12.3% | | Total | 301,005 | 98.8% | 412,049 | 99.1% | [Cost of Revenue, Gross Profit & Gross Margin](index=15&type=section&id=Cost%20of%20Revenue%2C%20Gross%20Profit%20%26%20Gross%20Margin) For H1 2025, medical services cost of revenue decreased by **13.4%** to **RMB209.9 million**, while gross profit fell **46.9%** to **RMB89.6 million**, and gross margin declined to **29.4%** Medical Services Revenue, Cost, Gross Profit & Gross Margin (For the six months ended June 30) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Revenue | 301,005 | 412,049 | | Cost of revenue | 209,856 | 242,370 | | Gross profit | 91,149 | 169,679 | | Gross margin | 30.3% | 41.2% | - Cost of revenue for medical services was **RMB209.9 million**, a **13.4% year-over-year decrease**[47](index=47&type=chunk) - Gross profit was **RMB89.6 million**, a **46.9% year-over-year decrease**; gross margin decreased from **40.6% to 29.4%**, primarily due to reduced demand for pediatric and obstetrics & gynecology medical services[48](index=48&type=chunk) [Operating Expenses](index=18&type=section&id=Operating%20Expenses) Selling expenses increased to **RMB33.9 million**, while administrative and R&D expenses decreased to **RMB59.1 million** and **RMB1.8 million**, respectively, alongside significant asset impairment losses - Selling expenses were **RMB33.9 million**, an **increase of 3.4% year-over-year**, primarily due to enhanced market penetration efforts[49](index=49&type=chunk) - Administrative expenses were **RMB59.1 million**, a **decrease of 2.8% year-over-year**, mainly due to cost reduction and improved operational efficiency[50](index=50&type=chunk) - Research and development expenses were **RMB1.8 million**, an **18.2% year-over-year decrease**, primarily due to reduced R&D activities[51](index=51&type=chunk) - An **impairment loss on non-current assets of RMB33.7 million** was recorded, comprising an **impairment loss on property, plant and equipment of RMB21.2 million** and a **goodwill impairment loss of RMB12.5 million**, mainly due to reduced demand for pediatric and obstetrics & gynecology services and lower-than-expected operating results[52](index=52&type=chunk) - A **net impairment loss on financial assets of RMB1.6 million** was recorded, primarily due to impairment loss on amounts due from related parties[53](index=53&type=chunk) [Financial Income and Expenses](index=19&type=section&id=Financial%20Income%20and%20Expenses) For H1 2025, finance income decreased to **RMB1.7 million** due to lower interest and exchange rate volatility, while finance costs were **RMB3.6 million**, mainly from lease interest - Finance income decreased from **RMB2.8 million to RMB1.7 million**, primarily due to lower interest income and fluctuations in exchange gains/losses[54](index=54&type=chunk) - Finance costs were **RMB3.6 million**, mainly comprising interest expenses related to lease payments[54](index=54&type=chunk) [Income Tax Expense](index=19&type=section&id=Income%20Tax%20Expense_FinancialReview) Income tax expense decreased by **25.9%** to **RMB17.7 million**, primarily due to the Group's loss and a **RMB9.0 million** deferred tax asset reversal - Income tax expense was **RMB17.7 million**, a **25.9% year-over-year decrease**[55](index=55&type=chunk) - The decrease was primarily due to the Group recording a loss and a **RMB9.0 million reversal of deferred tax assets** from wholly-owned subsidiaries[55](index=55&type=chunk) [Loss for the Period](index=19&type=section&id=Loss%20for%20the%20Period) For H1 2025, the Group reported a **loss of RMB58.8 million**, a significant shift from the **RMB48.3 million profit** in the prior period - For the six months ended June 30, 2025, the Group recorded a **loss of RMB58.8 million**, compared to a **profit of RMB48.3 million** in the prior period[56](index=56&type=chunk) [Balance Sheet Items](index=20&type=section&id=Balance%20Sheet%20Items) Inventories, trade receivables, and trade payables all decreased, reflecting a decline in medical business and reduced procurement - Inventories decreased by **16.6%** from **RMB15.7 million to RMB13.1 million**, primarily due to a decline in medical business[57](index=57&type=chunk) - Trade receivables decreased by **38.3%** from **RMB46.2 million to RMB28.5 million**, primarily due to a year-over-year decrease in medical business[58](index=58&type=chunk) - Trade payables decreased by **24.1%** from **RMB29.9 million to RMB22.7 million**, primarily due to reduced usage and procurement of pharmaceuticals and medical consumables[59](index=59&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and cash equivalents decreased by **6.4%** to **RMB331.9 million** as of June 30, 2025, with no significant investments, borrowings, or contingent liabilities, and ongoing monitoring of exchange rate risk - Cash and cash equivalents were **RMB331.9 million**, a **6.4% decrease** compared to December 31, 2024[60](index=60&type=chunk) - For the six months ended June 30, 2025, the Group had **no significant investments, acquisitions, or disposals** of subsidiaries, associates, and joint ventures[61](index=61&type=chunk)[62](index=62&type=chunk) - Capital expenditure was **RMB5.3 million**, a **34.6% year-over-year decrease**, primarily due to reduced related procurement in H1 2025[63](index=63&type=chunk) - The Group had **no borrowings** as of June 30, 2025, and December 31, 2024, thus the gearing ratio is not applicable[64](index=64&type=chunk)[70](index=70&type=chunk) - The Group primarily operates in China, with most transactions settled in RMB, and continuously monitors foreign exchange rate risks[65](index=65&type=chunk) - As of June 30, 2025, there were **no contingent liabilities, guarantees, pledges of assets, or contractual obligations** that would have a material impact on the financial position or operating results[66](index=66&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) [Employees and Remuneration Policy](index=22&type=section&id=Employees%20and%20Remuneration%20Policy) As of June 30, 2025, the Group had **1,233 employees** with total staff costs of **RMB161.1 million**, and remuneration is performance-based, including benefits and share schemes - As of June 30, 2025, the Group had **1,233 employees** (2024: 1,258 employees)[71](index=71&type=chunk) - Total staff costs were **RMB161.1 million** (2024: RMB172.2 million)[71](index=71&type=chunk) - Remuneration is determined based on employee performance, skills, qualifications, and experience, and includes social insurance, housing provident fund, performance bonuses, and discretionary bonuses[71](index=71&type=chunk) - The Group has adopted a **restricted share award scheme and an employee share scheme** to attract, retain, and supervise key employees[71](index=71&type=chunk) [Interim Dividend](index=22&type=section&id=Interim%20Dividend) The Board does not recommend an interim dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025[72](index=72&type=chunk) [Corporate Governance and Other Information](index=23&type=section&id=Corporate%20Governance%20and%20Other%20Information) The Group adheres to high corporate governance standards, complies with the Standard Code for Securities Transactions, addressed a disciplinary action, and reported no significant post-period events or listed securities transactions [Corporate Governance Code](index=23&type=section&id=Corporate%20Governance%20Code) The Company complies with the Corporate Governance Code, except for the combined Chairman and CEO roles, which the Board believes benefits the Group's strategy - The Company has complied with all applicable code provisions of the Corporate Governance Code, except for **Code Provision C.2.1** (which states that the roles of Chairman and Chief Executive Officer should be separate)[73](index=73&type=chunk) - **Mr. Jason ZHOU** serves as both Chairman and Chief Executive Officer, an arrangement the Board believes benefits the Group's business prospects, management, and overall strategic direction[73](index=73&type=chunk) [Standard Code for Securities Transactions](index=23&type=section&id=Standard%20Code%20for%20Securities%20Transactions) The Company adopted the Standard Code for directors' securities transactions, and all directors and relevant employees confirmed compliance - The Company has adopted the **Standard Code** as its code of conduct for directors' securities transactions and has established guidelines for relevant employees that are no less exacting than the Standard Code[74](index=74&type=chunk) - All directors and relevant employees have confirmed compliance with the Standard Code and the Company's guidelines for securities transactions for the six months ended June 30, 2025[74](index=74&type=chunk) [Disciplinary Action Statement](index=24&type=section&id=Disciplinary%20Action%20Statement) The Stock Exchange issued a disciplinary action statement on June 11, 2025, against the Company and directors for Listing Rule breaches, with all required training now completed - The Stock Exchange issued a **disciplinary action statement** against the Company, three executive directors, and three independent non-executive directors on **June 11, 2025**[75](index=75&type=chunk) - The Stock Exchange Listing Committee alleged that the Company violated several Listing Rules by failing to comply with announcement, circular, and/or shareholder approval requirements for providing financial assistance to connected persons[75](index=75&type=chunk) - The relevant directors breached their obligations under **Listing Rules 3.08 and 3.09B(2)** by failing to use their best endeavors to ensure the Company's compliance with internal controls and the Listing Rules[75](index=75&type=chunk) - All relevant directors have completed the training provided by a Stock Exchange-approved training institution within the stipulated timeframe[76](index=76&type=chunk) [Purchase, Sale or Redemption of Listed Securities](index=24&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Listed%20Securities) Neither the Company nor its subsidiaries purchased, sold, or redeemed any listed securities during the six months ended June 30, 2025 - For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[77](index=77&type=chunk) [Audit Committee](index=25&type=section&id=Audit%20Committee) The Audit Committee, chaired by Mr. Sun Hongbin, reviewed the Group's unaudited H1 2025 interim results, confirming their preparation according to accounting standards and adequate disclosure - The Audit Committee comprises **Mr. Sun Hongbin (Chairman)**, Mr. Jiang Yanfu (Independent Non-executive Director), and Mr. Yang Yuelin (Non-executive Director)[78](index=78&type=chunk) - The Audit Committee has reviewed the Group's unaudited interim results for the six months ended June 30, 2025, and considers them prepared in accordance with relevant accounting standards and adequately disclosed[78](index=78&type=chunk) [Post-Reporting Period Events](index=25&type=section&id=Post-Reporting%20Period%20Events) The Group reported no significant events between June 30, 2025, and the date of this announcement - The Group had no significant events between June 30, 2025, and the date of this announcement[79](index=79&type=chunk) [Publication of Interim Results Announcement and Interim Report](index=25&type=section&id=Publication%20of%20Interim%20Results%20Announcement%20and%20Interim%20Report) This interim results announcement is published on the Stock Exchange and Company websites, with the full interim report to follow for shareholders - This interim results announcement is published on the **Stock Exchange website (www.hkexnews.hk)** and the **Company's website (www.ncich.com.cn)**[80](index=80&type=chunk) - The interim report, containing all information required by the Listing Rules, will be dispatched to shareholders and published on the aforementioned websites in due course[80](index=80&type=chunk) [Definitions](index=25&type=section&id=Definitions) This section defines key terms and abbreviations used in the announcement to ensure clear understanding of the report content - This section lists definitions for key terms such as the **Board, Audit Committee, Beijing Children's Hospital, Corporate Governance Code, China, the Company, Directors, DRG/DIP payment method, Employee Share Scheme, the Group, Hong Kong, Hong Kong Financial Reporting Standards, HK$, Listing Rules, RMB, Standard Code, Remuneration Committee, Restricted Share Award Scheme, Shares, Shareholders, Stock Exchange, year-over-year, and percentage**[81](index=81&type=chunk)[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk)[88](index=88&type=chunk) [Board of Directors Information](index=27&type=section&id=Board%20of%20Directors%20Information) As of this announcement, the Board of Directors comprises executive, non-executive, and independent non-executive directors, including Mr. Jason ZHOU and Dr. Ma Jing - As of the date of this announcement, the Board of Directors comprises **three executive directors, four non-executive directors, and four independent non-executive directors**[87](index=87&type=chunk) - The executive directors are **Mr. Jason ZHOU, Ms. Xin Hong, and Mr. Xu Han**[87](index=87&type=chunk) - The independent non-executive directors are **Mr. Wu Guanxiong, Mr. Sun Hongbin, Mr. Jiang Yanfu, and Dr. Ma Jing**[87](index=87&type=chunk)

Core Viewpoint - New Century Healthcare (01518.HK) announced that it will hold a board meeting on August 27, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] Summary by Category - Company Announcement - The board meeting is scheduled for August 27, 2025, to discuss the interim performance of the company [1] - The interim results will cover the period ending June 30, 2025 [1]

1518 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 新世紀醫療控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二五年八月二十七日（星期三）舉行董事會會議，藉以（其中包括）考慮 及批准刊發本公司及其附屬公司截至二零二五年六月三十日止六個月之中期 業績，以及處理其他事項。 承董事會命 新世紀醫療控股有限公司 董事長、執行董事兼首席執行官 Jason ZHOU先生 中國北京，二零二五年八月十三日 於本公告日期，董事會成員包括執行董事Jason ZHOU先生、辛紅女士及徐瀚先生；非執行董 事王思業先生、李素玉女士、楊躍林先生及解強先生；及獨立非執行董事吳冠雄先生、孫洪 斌先生、姜彥福先生及馬晶博士。 董事會會議召開日期 ...

Core Viewpoint - New Century Healthcare (01518.HK) has issued a profit warning, expecting a loss attributable to shareholders between RMB 60 million and 70 million for the six months ending June 30, 2025, marking a significant decline from a net profit of RMB 25.2 million in the same period of 2024 [1][3]. Financial Performance - The company reported a revenue decline of 9.28% to RMB 846 million in 2024, with net profit plummeting by 43.71% to RMB 47.38 million, and a decrease in gross margin from 43.63% in 2023 to 40.75% [3]. - The shift from profit to loss in the first half of 2025 is attributed to reduced demand for pediatric and obstetric services, impairment losses on goodwill and other long-term assets, and the reversal of deferred tax assets [3]. Regulatory Issues - New Century Healthcare and several directors faced disciplinary action from the Hong Kong Stock Exchange due to violations related to connected transactions, resulting in a loss of over RMB 100 million [4]. - The Hong Kong Stock Exchange has mandated the company to conduct an independent internal review, and all involved directors are required to undergo training [4]. Company Overview - New Century Healthcare is a private medical group focused on providing high-quality medical services to children and women, with its first hospital established in 2002 and officially operating since 2006 [7].